Skip to search formSkip to main contentSkip to account menu

ozanimod

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndansOxadiazoles

Narrower (1)

RPC1063

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and…
Objective: Compare safety of ozanimod versus once-weekly, intramuscular interferon (IFN) β-1a in relapsing multiple sclerosis… 
2018
2018
Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple…
Objective: Compare efficacy and safety of ozanimod versus interferon (IFN) β-1a in RMS. Background: Ozanimod is an oral, once… 
2018
2018
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in…
Objective: Evaluate efficacy of ozanimod in pre-planned patient subgroups. Background: Ozanimod is an oral, once-daily… 
2018
2018
Ozanimod, an Oral S1P Receptor Modulator, Is Effective and Well-Tolerated in the Long-Term Treatment of Moderate to Severe Ulcerative Colitis: P-012
2016
2016
Ozanimod Treatment for Ulcerative Colitis.
To the Editor: The extensive exclusion criteria that were used in the TOUCHSTONE trial conducted by Sandborn et al. (May 5 issue… 
2016
2016
Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis (P3.023)
OBJECTIVE: Demonstrate long-term efficacy and safety of low (LD, 0.5mg) and high (HD, 1mg) dose Ozanimod. BACKGROUND: Ozanimod… 
2016
2016
Ozanimod: a better or just another S1P receptor modulator?
2016
2016
857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in…
2016
2016
Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension: 571
2015
2015
Digestive Disease Week.
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)